Migraine Management

Jerry W. Swanson, MD, is a consultant in the Department of Neurology and Professor of Neurology in the Mayo Clinic College of Medicine and Science. Dr. Swanson received his medical degree from the Feinberg School of Medicine at Northwestern University in Chicago. He completed a neurology residency at Mayo Clinic. He earned the Master of Health Professions degree at the University of Illinois at Chicago. He has been on the staff of Mayo Clinic in Rochester, Minn., since 1982. He is former chair of the Headache Division in the Department of Neurology and founding director of the headache medicine fellowship at Mayo Clinic in Minnesota. Dr. Swanson is board-certified in Neurology and in the subspecialty of Headache Medicine. He has written extensively about headache and other neurologic disorders. Swanson has made more than 100 presentations at national and international meetings, published more than 60 peer-reviewed articles, and numerous book chapters; he is an associate editor for the journal Headache and is a neurology editor for MayoClinic.com, a leading site for health information for the public. He has co-edited two books including The Mayo Clinic on Headache, a highly praised book for the lay public. He is a neurology editor for MayoClinic.com and is the headache topic editor and neurology editor-in-chief for UpToDate. He was a founding member for the UCNS Headache Medicine examination committee and is currently serving another term on the committee. He was the founding director of the Headache Medicine fellowship at Mayo Clinic in Rochester, Minn. Dr. Swanson has served in several leadership roles in the American Academy of Neurology and the American Headache Society and was a member of the International Headache Congress scientific program committee. He has been the recipient of the Mayo Medical School Dean’s Recognition Award. Dr. Manjit Matharu is a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. He received a BSc (First Class Honours) University of Manchester and MB, ChB (Honours Degree) University of Manchester. He earned a PhD at the University of London. He completed his residency in Neurology at The National Hospital for Neurology and Neurosurgery, The Royal London Hospital and Homerton Hospital in London in 2007. Dr Matharu’s major research interests include functional and structural imaging in Primary headaches, trigeminal autonomic cephalalgias and neurostimulation for intractable headaches. He has authored over 100 scientific papers. Dr. Matharu is the clinical and academic lead of the Headache Group at The National Hospital for Neurology and Neurosurgery, which is widely recognized as one of the foremost Headache Centers worldwide. He has lectured on headache topics both domestically and internationally.

*4 stars* "...covers evidence-based guidelines, special considerations, and diagnostic criteria of migraine subtypes, [and] the purpose is to be a clinical guide for practicing neurologists in all aspects of migraine management [which] is a worthy objective..... [W]ritten for healthcare practitioners, particularly neurologists or pain management specialists who treat the full spectrum of migraine disorders, [and] will help those specialists find the best treatment methods for these difficult cases.... [C]onsiders migraine in specific populations such as elderly patients, children and adolescents, and pregnant patients. It explores different types of migraine -- vestibular, retinal, hemiplegic – as well as future directions for migraine research. [A] quick reference, and the writing is succinct.... [P]rovides a very comprehensive overview of migraine management, [and] can be read cover to cover or referenced on an as-needed basis." --©Doody’s Review Service, 2024, Adil F. Niaz, DO (Yale School of Medicine)

• Section I. Migraine Management1. Non-specific analgesics, combination analgesics, and antiemetics2. The 5-HT1B and 5-HT1D Agonists in Acute Migraine Therapy: Ergotamine, dihydroergotamine, and the triptans3. 5-HT1F agonists4. CGRP receptor antagonists (Gepants)5. Preventive treatment of migraine: Non-specific oral agents6. OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment7. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention8. Nutraceuticals in migraine9. Interventional treatments10. Biobehavioral treatments of migraine11. Physical treatment of migraine12. Neuromodulation in migraineSection II. Guidelines13. Evidence-based symptomatic treatment of migraine14. Evidence-based preventive treatment of migraineSection III. Special Cases/Situations15. Treatment in the emergency department16. Special considerations in migraine during pregnancy and lactation17. Special considerations in management of migraine in the elderly18. Management of medication overuse headacheSection IV. Outcome Measures19. Outcome Measures for Migraine: Measuring the impact of migraine and results of migraine treatmentSection V. Diagnosis and Treatment of Other Migraine Subtypes20. Menstrually associated migraine21. Hemiplegic migraine22. Migraine with brainstem aura23. Retinal migraine24. Vestibular migraine and persistent postural perceptual dizziness25. Status migrainosus26. Persistent aura, visual snow, and other visual symptoms27. Migrainous infarction28. Migraine in children and adolescents: Assessment and diagnosis 29. Management of migraine in children and adolescentsSection VI. Comorbidities of Migraine30. Psychiatric comorbidities of migraine31. Relationship of migraine and other forms of chronic pain32. Comorbidities of migraine: Sleep disorders33. The evolving concept of multimorbidity and migraineSection VII. Future Directions34. Healthcare disparities faced by patients with migraine and potential mitigation strategies35. Emerging and future directions of migraine research and treatment